Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.42 |
| ▸ | TUBB | P07437 | 1/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.42 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.42 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.42 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1751993 | 0.82 | SMN1; SMN2 (0.62) | SMN1; SMN2L3MBTL1KMT2AMEN1ATM | |
| SCHEMBL19163738 | 0.82 | SMN1; SMN2 (0.68) | SMN1; SMN2L3MBTL1KMT2AMEN1ATM | |
| SCHEMBL5834129 | 0.80 | SMN1; SMN2 (0.61) | SMN1; SMN2L3MBTL1KMT2AMEN1ATM | |
| SCHEMBL4644491 | 0.79 | POLB (0.51) | L3MBTL1KMT2AMEN1ATMALDH1A1 | |
| SCHEMBL10500417 | 0.78 | TDP1 (0.55) | L3MBTL1ATMALDH1A1KDM4ETUBB4A | |
| Hydrochloric Acid SCHEMBL7314768 | 0.78 | SMN1; SMN2 (0.59) | SMN1; SMN2L3MBTL1KMT2AMEN1ATM | |
| SCHEMBL10792928 | 0.78 | SMN1; SMN2 (0.59) | SMN1; SMN2L3MBTL1KMT2AMEN1ATM | |
| SCHEMBL2058958 | 0.78 | SMN1; SMN2 (0.59) | SMN1; SMN2L3MBTL1KMT2AMEN1ATM | |
| SCHEMBL28517396 | 0.78 | SMN1; SMN2 (0.59) | SMN1; SMN2L3MBTL1KMT2AMEN1ATM | |
| SCHEMBL28875517 | 0.77 | TDP1 (0.54) | L3MBTL1ATMALDH1A1KDM4ETUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6576791-B1 | Local anesthetic compounds and uses | THERAVANCE, INC. | 2003-06-10 | — | — | US | disclosed |
| US-20030044845-A1 | Novel therapeutic agents for membrane transporters | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-03-06 | — | — | US | disclosed |
| US-6495681-B1 | PRODUCING LOCAL ANESTHESIA OF LONG-DURATION. THE COMPOUNDS OF THIS INVENTION ARE MULTIBINDING COMPOUNDS THAT COMPRISE FROM 2 TO 10 LIGANDS COVALENTLY ATTACHED TO A LINKER OR LINKERS, EACH LIGAND BEING CAPABLE OF BINDING TO A LIGAND BINDING SITE | THERAVANCE INC. | 2002-12-17 | — | — | US | disclosed |
| US-6462034-B1 | MULTIBINDING COMPOUNDS CONTAINING A SYMETRICAL DIAMINOTETRA-ETHERDODECANE RING WITH TWO SECONDARY AMIDE AND ADDITIONAL SUBSTITUENTS; VOLTAGE GATED SODIUM CHANNEL MODULATORS; LONG DURATION | THERAVANCE, INC. | 2002-10-08 | — | — | US | disclosed |
| US-6337423-B1 | BIND TO VOLTAGE-GATED SODIUM ION CHANNELS TO MODULATE ACTIVITY | ADVANCED MEDICINE, INC. | 2002-01-08 | — | — | US | disclosed |
| WO-1999064045-A9 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | ADVANCED MEDICINE INC (US) | 2001-07-05 | — | — | WO | disclosed |
| EP-1089749-A4 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | ADVANCED MEDICINE INC (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1089749-A1 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | Advanced Medicine, Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1066245-A4 | NOVEL LOCAL ANESTHETIC COMPOUNDS AND USES | ADVANCED MEDICINE INC (US) | 2001-01-24 | — | — | EP | disclosed |
| EP-1066245-A1 | NOVEL LOCAL ANESTHETIC COMPOUNDS AND USES | Advanced Medicine, Inc. (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999064045-A1 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1999051565-A9 | NOVEL LOCAL ANESTHETIC COMPOUNDS AND USES | ADVANCED MEDICINE INC (US) | 1999-12-02 | — | — | WO | disclosed |
| WO-1999051565-A1 | NOVEL LOCAL ANESTHETIC COMPOUNDS AND USES | ADVANCED MEDICINE, INC. (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030044845-A1 | Novel therapeutic agents for membrane transporters | SLC47A2, SLC8B1, SLC47A1 | SMN1; SMN2 4740/4885L3MBTL1 3630/4885KMT2A 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.